17December

Staten Biotechnology B.V. and Novo Nordisk A/S announce collaboration to develop ... Read more

23November

Oral semaglutide demonstrates favourable cardiovascular safety profile and signi ... Read more

22November

Oral semaglutide demonstrates greater reductions in both HbA1c and body weight c ... Read more

02November

Embark and Novo Nordisk enter collaboration to discover novel therapeutics for o ... Read more

14January

Novo Nordisk A/S - Share repurchase programme ... Read more

07January

Novo Nordisk A/S - Share repurchase programme ... Read more

21December

Novo Nordisk A/S: Share repurchase programme ... Read more

17December

Novo Nordisk A/S - Share repurchase programme ... Read more

01February

Financial statement for the full year of 2018,

06February

Cut-off date for shareholders' proposals in connection with the Annual General Meeting (AGM), Copenhagen

21March

Annual General Meeting, Copenhagen

03May

Financial statement for the first three months of 2019,

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
Annual Report 2017 


Click here to find further information

 
Q3 2018 financial results


Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.


ADA investor and analyst event